CDT Equity (CDT) Amortizatization of Intangibles (2023 - 2026)
CDT Equity's (CDT) quarterly Amortizatization of Intangibles came in at $311000.0 in Q1 2026, down 15.72% YoY from $369000.0 in Q1 2025, and little changed on a QoQ basis from $311000.0 in Q4 2025.
CDT Equity (CDT) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
CDT Equity (CDT) has 4 years of Amortizatization of Intangibles data on file, last reported at $311000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 15.72% year-over-year to $311000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $722000.0 (down 55.24% YoY) and the FY2025 annual result came in at $1.4 million, down 13.57% from the prior year.
- Amortizatization of Intangibles held at $311000.0 in Q1 2026, from $311000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $441000.0 in Q2 2024 to a low of $100000.0 in Q3 2025.
- A 4-year average of $354666.7 and a median of $369000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 12.56% in 2025, down 76.96% in 2025.
- Tracing CDT's Amortizatization of Intangibles over 4 years: stood at $435000.0 in 2023, then retreated by 15.17% to $369000.0 in 2024, then decreased by 15.72% to $311000.0 in 2025, then changed by 0.0% to $311000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $311000.0 (Q1 2026), $311000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 311,000.00 |
| Mar 31, 2026 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 434,000.00 |
| Sep 30, 2024 | 434,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Mar 31, 2024 | 422,000.00 |
| Mar 31, 2024 | 422,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Dec 31, 2023 | 435,000.00 |